Literature DB >> 16547766

Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model.

Winston S N Shim1, Wei Li, Li Zhang, Shiqi Li, Hwee Choo Ong, In-Chin Song, Akanksha Bapna, Ruowen Ge, Yean Teng Lim, Seng Chye Chuah, Eugene K W Sim, Philip Wong.   

Abstract

This study investigates the long-term angiogenic effects of ANG-1 and VEGF in a swine chronic myocardial ischemia model. Four-weeks after gradual occlusion of the left circumflex coronary artery by ameroid constrictor, animals were injected with recombinant adenoviral vectors carrying either human ANG-1 (n=9), human VEGF(165) (n=10) or empty vector (n=7) into the left ventricle free wall supplied by the constricted artery. Left ventricular perfusion in animals that received AdANG-1 (3.25+/-0.16 ml/min/g, p<0.05) recovered robustly 4 weeks after gene transfer while ischemia persisted in the AdVEGF (1.09+/-0.13 ml/min/g) and empty vector (1.20+/-0.03 ml/min/g) groups. Microvascular densities in the left ventricles of animals that received AdANG-1 (19.61+/-1.76/0.572 mm(2) myocardial tissue, p<0.05) and AdVEGF (18.17+/-1.43/0.572 mm(2) myocardial tissue, p<0.05) were significantly higher than animals that received empty vector (13.53+/-0.92/0.572 mm(2) myocardial tissue) 12 weeks after gene transfer. ANG-1, but not VEGF, contributed to enhanced regional perfusion by increasing arteriolar density (1.9+/-0.4/0.572 mm(2) myocardial tissue vs. 0.7+/-0.2/0.572 mm(2) myocardial tissue, p<0.05) of large-sized (50-100 microm) arterioles. These data demonstrate that gene transfer of ANG-1 and VEGF enhances angiogenesis, but ANG-1 promotes sustained improvement of ventricular perfusion that expedites recovery of ischemic myocardium via arteriogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547766     DOI: 10.1007/s11373-006-9082-x

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  7 in total

Review 1.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

2.  Serum-deprived human multipotent mesenchymal stromal cells (MSCs) are highly angiogenic.

Authors:  Adam Oskowitz; Harris McFerrin; Miriam Gutschow; Mary Leita Carter; Radhika Pochampally
Journal:  Stem Cell Res       Date:  2011-01-31       Impact factor: 2.020

Review 3.  Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease.

Authors:  Nirat Beohar; Jonathan Rapp; Sanjay Pandya; Douglas W Losordo
Journal:  J Am Coll Cardiol       Date:  2010-10-12       Impact factor: 24.094

4.  Improved Cardiac Function Following Ischemia Reperfusion Injury Using Exercise Preconditioning and L-Arginine Supplementation via Oxidative Stress Mitigation and Angiogenesis Amelioration.

Authors:  Kamal Ranjbar
Journal:  Cardiovasc Toxicol       Date:  2022-05-22       Impact factor: 2.755

Review 5.  Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.

Authors:  Gabor M Rubanyi
Journal:  Mol Ther       Date:  2013-02-12       Impact factor: 11.454

6.  Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion.

Authors:  Qing Qin; Juying Qian; Jianying Ma; Lei Ge; Junbo Ge
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 7.  Therapeutic Targets for Regulating Oxidative Damage Induced by Ischemia-Reperfusion Injury: A Study from a Pharmacological Perspective.

Authors:  Walter Ángel Trujillo-Rangel; Leonel García-Valdés; Miriam Méndez-Del Villar; Rolando Castañeda-Arellano; Sylvia Elena Totsuka-Sutto; Leonel García-Benavides
Journal:  Oxid Med Cell Longev       Date:  2022-04-11       Impact factor: 7.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.